These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1103 related items for PubMed ID: 16755193

  • 1. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 6. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Dec; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 8. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 21; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 21; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 10. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 11. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D.
    Can J Cardiol; 2005 May 15; 21(7):569-75. PubMed ID: 15940354
    [Abstract] [Full Text] [Related]

  • 12. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 May 15; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 13. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Eur Heart J; 2005 Nov 15; 26(22):2361-7. PubMed ID: 16105846
    [Abstract] [Full Text] [Related]

  • 14. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Nov 15; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 15; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 16. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S, Arora RR.
    Am J Ther; 2010 Mar 15; 17(1):e11-23. PubMed ID: 20090429
    [Abstract] [Full Text] [Related]

  • 17. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2005 Jan 06; 125(1):38-40. PubMed ID: 15643463
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 06; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 19. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep 06; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 20. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S, Narula J, Marelli C, Cesario D.
    Am J Cardiol; 2006 Mar 15; 97(6):921-5. PubMed ID: 16516603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.